Compound profile
Epitalon
EmergingAlso known as: Epithalon · Ala-Glu-Asp-Gly
A synthetic tetrapeptide associated with pineal peptide research and aging biology conversations. Evidence is largely historical/preclinical with limited modern RCT coverage.
Overview
Epitalon, also spelled Epithalon, is a synthetic tetrapeptide with the sequence alanine-glutamic acid-aspartic acid-glycine (AEDG). It was developed by Vladimir Khavinson's laboratory at what became the St. Petersburg Institute of Bioregulation and Gerontology, growing out of a research program Khavinson began in the 1970s studying epithalamin, a longer natural extract from the pineal gland that had shown age-related effects in earlier Soviet animal research. Epitalon was designed as a simplified, synthetic analogue built around what Khavinson's group identified as the shortest bioactive fragment of that longer natural compound.
The research underpinning Epitalon sits mostly within a specific scientific tradition, decades of work from Khavinson's own institute and closely affiliated Russian research groups, exploring peptide bioregulation and pineal gland biology, much of it published in Russian-language or Eastern European journals rather than mainstream international literature. Some of the more attention-getting claims associated with Epitalon involve telomerase activation and telomere lengthening in cell culture, including a more recent independent replication at a UK university, but human trials directly demonstrating meaningful telomere lengthening or lifespan extension from Epitalon administration in people do not exist.
Epitalon has never been approved as a drug by the FDA or, as far as broadly available records indicate, for general public use elsewhere, and it is sold internationally only as an unregulated research chemical. Its reputation in longevity and biohacking circles runs well ahead of what has actually been independently replicated and published in rigorous, modern human trials.
Mechanism (plain language)
Linked in older literature to telomerase and pineal regulatory hypotheses. Mechanistic certainty in humans is low.
How it works
Epitalon's proposed mechanisms center on two related ideas: pineal gland regulation and telomerase activity. The pineal gland produces melatonin and is involved in circadian rhythm regulation, and Khavinson's broader research program framed peptides like Epitalon as "bioregulators" that could help restore more youthful patterns of gene expression in aging tissue, in this case tied to pineal and circadian function.
The more widely cited mechanistic claim involves telomerase, the enzyme that helps maintain the protective caps (telomeres) on the ends of chromosomes, which shorten with each cell division and are linked to cellular aging. Cell culture studies, including a relatively recent independent replication, have reported that Epitalon exposure can activate telomerase and increase telomere length in certain human cell lines. That is a real and specific finding worth noting, but it comes from isolated cells in a dish, not from a controlled human trial showing that administering Epitalon to a person measurably lengthens telomeres in their body or produces any downstream health or lifespan benefit as a result.
What research suggests
Russian and preclinical literature discusses geroprotective and circadian themes. Independent, large modern trials in athletic populations are lacking.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Telomerase activation in cell culture
Laboratory studies, including an independent 2025 replication, report that Epitalon can activate telomerase and increase telomere length in certain human cell lines.
Chromatin activation in older human cells
An older human cellular study reported that Epitalon activated chromatin in lymphocytes taken from aged people, a finding often cited in discussions of its geroprotective potential.
Circadian and pineal-related themes
Russian and preclinical literature discusses proposed effects on pineal gland function and circadian regulation, consistent with Epitalon's origins as an epithalamin-derived compound.
Uncertainties & risks
Longevity marketing often outruns reproducible evidence. Translation, replication, and product identity issues are significant. Treat as curiosity for diligence, not established practice.
The evidence gap between Epitalon's longevity reputation and what has actually been demonstrated in people is substantial. The telomerase and telomere findings that generate the most excitement come from cell culture experiments, not from controlled trials showing that Epitalon administration lengthens telomeres or extends healthy lifespan in living humans, and no large-scale, independently replicated human trial has established that. Much of the supporting literature originates from a small number of closely affiliated Russian research groups rather than broad international replication, which makes it harder to weigh against typical international clinical trial standards. Longevity marketing around Epitalon regularly outruns what the reproducible science actually supports, and translation issues, both scientific translation from cell models to human physiology, and literal translation of older Russian-language research, complicate independent verification. Product identity and purity are separate concerns layered on top of the science, since it is sold only as an unregulated research chemical with no FDA approval or long-term human safety monitoring. It is worth treating as a genuine area of scientific curiosity rather than an established longevity practice.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.